MDMA has been in the news a lot over the past few years, and in the last few days with the recent resubmission for FTA approval. Researchers around the world have been studying whether MDMA, when used carefully in a therapeutic setting alongside trained therapists, could help people heal from conditions that haven’t responded well to existing treatments.
The research is still evolving. Some of it is very promising. Some of it- is early. And some of it has hit significant regulatory roadblocks. This article reviews what MDMA-assisted therapy has actually been studied for, what the results show, and where things stand right now, no hype just plain language results.
Before jumping into the results lets briefly review:
What Is MDMA-Assisted Therapy?
MDMA-assisted therapy is not the same as taking ecstasy at a party. In a therapeutic setting, pharmaceutical-grade MDMA is administered at a controlled dose during a structured therapy session that typically lasts six to eight hours. A trained therapist pair is present the entire time.
It appears that MDMA works by temporarily reducing the fear response in the brain while increasing feelings of trust, openness, and emotional connection. This creates a window in which people can approach painful memories, emotions, and relational experiences that would normally feel overwhelming and process them with their therapist in real time.
The therapy sessions are not isolated events. They are part of a larger therapeutic process that includes preparation sessions beforehand and integration sessions afterward, where the person makes sense of what came up and translates the experience into lasting change.
1. PTSD- The Most Studied Condition
Post-traumatic stress disorder is where the research on MDMA-assisted therapy is most developed. Over the past two decades, the nonprofit organization MAPS (Multidisciplinary Association for Psychedelic Studies) funded a series of clinical trials that became the most advanced psychedelic therapy research program in the world.
What the studies found
Across seven randomized controlled trials involving 280 adults with PTSD:
- Five out of six studies found that participants who received MDMA-assisted therapy had significantly greater reductions in PTSD symptoms compared to those who received therapy with a placebo.
- Between 42% and 86% of participants who received MDMA no longer met the diagnostic criteria for PTSD after treatment, compared to 25% to 33% in the placebo groups.
- Many participants in these studies had tried multiple other treatments without success. Some had lived with PTSD for decades.
Based on this data, the FDA granted MDMA “breakthrough therapy” designation for PTSD in 2017 a label reserved for treatments that show substantial improvement over what’s currently available.
What happened with FDA approval
Sadly, in August 2024, the FDA declined to approve MDMA-assisted therapy. The agency cited three concerns: insufficient evidence on how long the benefits last, incomplete safety data, and the potential for bias in the trials (many participants had used MDMA before and could tell whether they received the real drug or placebo).
This month (August 2026) the company behind the application (now called Resilient Pharmaceuticals) resubmitted its application without conducting a new large-scale trial. Instead, it provided additional safety data and referenced studies conducted by other groups, including a Veterans Affairs study with longer-term follow-up. The FDA has not yet confirmed whether it will accept the resubmission for review.
Research outside the United States
Australia became the first country in the world to make MDMA legally available as a medicine for PTSD, in July 2023. Authorized psychiatrists can prescribe it under strict conditions. By late 2025, approximately 87 patients had been treated with no serious adverse events reported. Australia has also published clinical practice guidelines for how to deliver the treatment.
Israel is generating some of the most urgent real-world data. A study at HaEmek Medical Center found that approximately 80% of Israeli soldiers who completed MDMA-assisted therapy for PTSD experienced significant symptom reduction, with most no longer meeting diagnostic criteria. This research was accelerated by the surge in PTSD cases following the October 7, 2023 attacks. A larger trial (168 participants across two sites) is now recruiting, and it is breaking new ground by comparing group-based MDMA therapy to individual sessions.
The Netherlands is running the HI-MAP study at ARQ National Psychotrauma Centre, testing high-intensity inpatient MDMA-assisted therapy for people with treatment-resistant PTSD, specifically those who did not improve after EMDR or prolonged exposure therapy.
Canada allows case-by-case compassionate access through Health Canada’s Special Access Program, though approvals have declined sharply since early 2024.
2. Social Anxiety in Autistic Adults
This is one of the most striking, and least well-known, areas of MDMA research!
Social anxiety affects a very large proportion of autistic adults, and treatment options are limited. Standard anti-anxiety medications show poor effectiveness in this population, and most cognitive-behavioural therapy (CBT) protocols are designed for neurotypical brains.
What the study found
A 2018 pilot study, led by researcher Alicia Danforth and published in Psychopharmacology, enrolled 12 autistic adults with marked to very severe social anxiety. Participants received either two sessions of MDMA-assisted therapy or placebo.
- The MDMA group showed significantly greater reductions in social anxiety compared to placebo.
- The effect size was very large (d = 1.4), meaning the difference between the groups was substantial, not subtle.
- The improvements held at six-month follow-up (d = 1.1), and for most participants, social anxiety continued to improve slightly even after the treatment phase ended.
This is a small study, and the results need to be replicated. However, they are notable because there are currently no approved pharmacological treatments for social anxiety in autistic adults. For a population that has been largely overlooked by psychiatric research, even a small pilot study with strong results matters a great deal.
What’s happening now
A larger, more rigorous trial is underway across four countries: the UK, USA, Australia, and Canada with 40 to 44 participants. It is designed with a neurodiversity-affirming framework: the goal is to reduce suffering and support self-acceptance, not to “normalize” autistic people. In Australia, a separate multi-site trial is recruiting approximately 150 young autistic adults.
3. Alcohol Use Disorder
Can MDMA help people recover from alcohol addiction? The early evidence is intriguing.
What the study found
The Bristol Imperial MDMA in Alcoholism (BIMA) study was the first clinical trial of MDMA-assisted therapy for any substance use disorder. Fourteen people with alcohol use disorder who had recently completed detox received two sessions of MDMA-assisted therapy alongside an eight-week course of recovery-based psychotherapy.
- At nine months after detox, the average alcohol consumption had dropped from 130.6 units per week to 18.7 units per week.
- Only 21% of the MDMA group were drinking heavily, compared to 75% in a comparison group that received standard treatment.
- Alcohol cravings decreased. Psychosocial functioning improved. MDMA was well tolerated with no unexpected adverse events.
This was an open-label study (not placebo-controlled), so the results should be interpreted cautiously. But the direction of the findings was strong enough to prompt larger follow-up trials.
What’s happening now
The U.S. Department of Veterans Affairs is running a randomized controlled trial of MDMA-assisted therapy for veterans with both PTSD and alcohol use disorder the first trial to study these two conditions together. In Australia, the MPATHY trial at the University of Sydney is also investigating MDMA combined with prolonged exposure therapy for people with comorbid PTSD and alcohol dependence.
4. Eating Disorders — Very Early Research
Eating disorders, particularly anorexia nervosa, have one of the highest mortality rates of any mental health condition and are notoriously difficult to treat. Many people with eating disorders also carry unresolved trauma, and the rigid thinking patterns that characterize these conditions often make it hard to engage fully in therapy.
Why researchers are interested
A 2025 review paper published in the Journal of Eating Disorders laid out the theoretical case for MDMA-assisted therapy in this area. The authors argued that MDMA’s ability to reduce fear responses, increase emotional openness, and promote cognitive flexibility could help break through the therapeutic impasses that are common in eating disorder treatment, especially when trauma is part of the picture.
Where the research stands
Honestly, it is very early. A Phase 2 trial for anorexia nervosa and binge eating disorder was registered by Resilient Pharmaceuticals (then Lykos Therapeutics) but was withdrawn before it started, likely due to the company’s regulatory challenges with the PTSD application.
A Phase 1 trial for bulimia nervosa is currently recruiting (as of 2026), comparing MDMA-assisted therapy with standard treatment. This is the first active clinical trial of MDMA specifically for an eating disorder population.
No completed clinical trials exist yet. But the theoretical rationale is compelling, and researchers are actively working to build the evidence base.
5. End-of-Life Anxiety
A small study explored whether MDMA-assisted therapy could help people experiencing anxiety and psychological distress related to a life-threatening illness. Five participants received low-dose MDMA (25mg) alongside therapy.
The results showed some improvements, but the study was very small and the dose was low. For end-of-life anxiety specifically, psilocybin currently has a much stronger evidence base, with larger trials showing significant and durable reductions in existential distress, depression, and anxiety in people facing terminal diagnoses.
MDMA may still have a role here, but right now the research is too limited to draw conclusions.
The Honest Picture
MDMA-assisted therapy is not a miracle cure for anything. Here is what we can say with confidence:
- For PTSD, the evidence is substantial and growing. Multiple randomized controlled trials show significant benefits, and one country (Australia) has already made it available as a medicine. The FDA rejected the U.S. application but the door is not closed.
- For social anxiety in autistic adults, the evidence is small but striking — a very large effect size in a population where nothing else has worked well.
- For alcohol use disorder, early results are encouraging, and larger trials are underway.
- For eating disorders, the theoretical case is strong but clinical evidence is just beginning to be gathered.
- For end-of-life anxiety, the data is too limited to draw conclusions.
Across all of these conditions, one theme is consistent: MDMA appears to work best when it is integrated with skilled psychotherapy. The drug is not the treatment. It creates the conditions, reduced fear, increased openness, enhanced connection, in which the real therapeutic work can happen more deeply and more effectively.
The research is ongoing. It is imperfect. And it is worth paying attention to.
Valentina Chichiniova, RCC is a Registered Clinical Counsellor at Emergence Counselling & Wellness in Vancouver, BC. She specializes in complex trauma, EMDR, Deep Brain Reorienting, and psychedelic-assisted psychotherapy. Valentina offers online therapy for clients across British Columbia.
Book a free consultation | Learn more about Valentina
References:
- Mitchell, J.M., et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27, 1025–1033.
- Danforth, A.L., et al. (2018). Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology, 236, 137–148.
- Sessa, B., et al. (2021). First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. Journal of Psychopharmacology, 35(4), 375–383.
- Brewerton, T.D., et al. (2025). Exploring MDMA-assisted therapy in eating disorders: mechanisms, clinical evidence, and future directions. Journal of Eating Disorders, 13.
- Multidisciplinary Association for Psychedelic Studies (MAPS). (2026). MAPS responds to report of progress for MDMA-assisted therapy for PTSD with FDA.
- Feduccia, A.A., & Mithoefer, M.C. (2018). MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction the mechanisms of action? Progress in Neuro-Psychopharmacology and Biological Psychiatry, 84, 221–228.
This is educational content based on published clinical research. It is not medical advice, a recommendation for any specific treatment, or a substitute for professional clinical consultation. MDMA remains a controlled substance in most jurisdictions and is not approved for therapeutic use in Canada or the United States.